Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib. [electronic resource]
Producer: 20160202ISSN:- 1460-2105
- Antineoplastic Agents -- administration & dosage
- Crizotinib
- Fibrosarcoma -- congenital
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic
- Gene Fusion
- Humans
- Infant
- Lamin Type A -- genetics
- Lung Neoplasms -- drug therapy
- Molecular Targeted Therapy
- Protein Kinase Inhibitors -- administration & dosage
- Pyrazoles -- administration & dosage
- Pyridines -- administration & dosage
- Receptor, trkA -- genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Spinal Neoplasms -- drug therapy
- Treatment Outcome
No physical items for this record
Publication Type: Case Reports; Letter
There are no comments on this title.
Log in to your account to post a comment.